Search results
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
Retina UK is a charity supporting people affected by inherited sight loss and investing in medical research to help make their challenges a thing of the past.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Dr Daniel Jackson discusses what images you are likely to have during a hospital appointment; how they are taken; why we take them; how we interpret them; and how this helps in the management and treatment of retinal conditions
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
A guide for professionals. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future. We also support professionals working with them.
A recording of the Retina UK Professionals' Conference on 8 July 2022. The Conference was held at the Macdonald Burlington Hotel in Birmingham and also online.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
Are you affected by inherited sight loss? We are here to help. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future.
